Osteoporosis International最新文献

{"title":"Notable lacking of bone mineral density measurement in cushing syndrome: a nationwide study based on the US insurance claim database.","authors":"Amirhossein Ghaseminejad-Raeini, Amir Human Hoveidaei, Fatemeh Zarepour, Seyed Pouya Taghavi, Amirhossein Shirinezhad, Alireza Azarboo, Amir Hekmat Hamrahian, Janet D Conway","doi":"10.1007/s00198-025-07418-z","DOIUrl":"https://doi.org/10.1007/s00198-025-07418-z","url":null,"abstract":"<p><p>This study examined the underuse of bone mineral density (BMD) testing in Cushing's syndrome patients, using a US insurance claims database. Despite osteoporosis risks, only 6.40% of 53,101 patients received BMD testing. The study underscores significant care gaps, particularly among males and older adults, necessitating improved screening efforts.</p><p><strong>Background: </strong>Cushing syndrome (CS) is caused by long-term exposure to elevated glucocorticoid levels, primarily due to chronic steroid use, though it can also result from pituitary tumors. This condition leads to significant bone mineral density (BMD) loss and a heightened risk of osteoporosis. Despite guidelines for BMD testing in at-risk patients, osteoporosis has remained underdiagnosed in CS. The prevalence of BMD measurement in this group in the US continues to be unknown, indicating a gap in care.</p><p><strong>Methods: </strong>We conducted a retrospective study using data from the PearlDiver Patient Records Database (2010-2020). Patients diagnosed with Cushing's syndrome who underwent BMD testing were included, while those with prior osteoporosis diagnoses were excluded. We analyzed patient demographics, comorbidities, and outcomes using t-tests, chi-squared tests, and logistic regression with significance set at p < 0.001.</p><p><strong>Results: </strong>Among 53,101 identified Cushing's syndrome patients, only 6.40% underwent bone mineral density (BMD) testing within two years of diagnosis. Females were significantly more likely to be tested (7.85% vs. 2.58%; p < 0.001), and those tested were younger (mean age: 62.79 vs. 65.21 years; p < 0.001). The Midwest region had the highest testing rate at 7.1%, and patients with commercial insurance had the highest testing frequency at 7.5%. Factors associated with reduced BMD testing included male gender (OR = 0.31; p < 0.001), older age (OR = 0.96; p < 0.001), and higher Elixhauser Comorbidity Index (ECI) scores (OR = 0.89; p < 0.001). Conversely, obesity (OR = 1.51; p < 0.001) and chronic kidney disease (OR = 1.38; p < 0.001) increased the likelihood of testing. Among those tested, 12.56% were diagnosed with osteoporosis, with older age and tobacco use significantly increasing the odds of diagnosis.</p><p><strong>Conclusion: </strong>Despite guideline recommendations, only 6.40% of patients with Cushing's syndrome underwent BMD screening. Among those screened, 12.56% were diagnosed with osteoporosis.. These findings highlight the need for improved adherence to screening guidelines, particularly for high-risk populations, to better manage and prevent osteoporosis in Cushing's syndrome patients.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized 25(OH)D and fall risk: overcoming challenges and enhancing clinical applications.","authors":"Yumei Zhong, Shanshan Liu, Xiaofeng Lv","doi":"10.1007/s00198-025-07451-y","DOIUrl":"https://doi.org/10.1007/s00198-025-07451-y","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensemble-learning approach improves fracture prediction using genomic and phenotypic data.","authors":"Qing Wu, Jongyun Jung","doi":"10.1007/s00198-025-07437-w","DOIUrl":"https://doi.org/10.1007/s00198-025-07437-w","url":null,"abstract":"<p><p>This study presents an innovative ensemble machine learning model integrating genomic and clinical data to enhance the prediction of major osteoporotic fractures in older men. The Super Learner (SL) model achieved superior performance (AUC = 0.76, accuracy = 95.6%, sensitivity = 94.5%, specificity = 96.1%) compared to individual models. Ensemble machine learning improves fracture prediction accuracy, demonstrating the potential for personalized osteoporosis management.</p><p><strong>Purpose: </strong>Existing fracture risk models have limitations in their accuracy and in integrating genomic data. This study developed and validated an innovative ensemble machine learning (ML) model that combines multiple algorithms and integrates clinical, lifestyle, skeletal, and genomic data to enhance prediction for major osteoporotic fractures (MOF) in older men.</p><p><strong>Methods: </strong>This study analyzed data from 5130 participants in the Osteoporotic Fractures in Men cohort Study. The model incorporated 1103 individual genome-wide significant variants and conventional risk factors of MOF. The participants were randomly divided into training (80%) and testing (20%) sets. Seven ML algorithms were combined using the SL ensemble method with tenfold cross-validation MOF prediction. Model performance was evaluated on the testing set using the area under the curve (AUC), the area under the precision-recall curve, calibration, accuracy, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and reclassification metrics. SL model performances were evaluated by comparison with baseline models and subgroup analyses by race.</p><p><strong>Results: </strong>The SL model demonstrated the best performance with an AUC of 0.76, accuracy of 95.6%, sensitivity of 94.5%, specificity of 96.1%, NPV of 95.1%, and PPV of 94.7%. Among the individual ML, gradient boosting performed optimally. The SL model outperformed baseline models, and it also achieved accuracies of 93.1% for Whites and 91.6% for Minorities, outperforming single ML in subgroup analysis.</p><p><strong>Conclusion: </strong>The ensemble learning approach significantly improved fracture prediction accuracy and model performance compared to individual ML. Integrating genomic and phenotypic data via the SL approach represents a promising advancement for personalized osteoporosis management.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.","authors":"Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli, Jean-Yves Reginster","doi":"10.1007/s00198-025-07440-1","DOIUrl":"10.1007/s00198-025-07440-1","url":null,"abstract":"<p><p>Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor agonists, teriparatide and abaloparatide, are effective at reducing fracture risk, real-world evidence (RWE) remains sparse. This study reviews and compares the anti-fracture efficacy of these agents, against each other and against other osteoporosis treatments using both RCTs and RWE. We systematically searched Medline, Embase, and Cochrane up to May 2024, focusing on RCTs and RWE studies reporting reduction in vertebral, non-vertebral, hip, or all fractures as primary endpoint. A network meta-analysis (NMA) was conducted, first through pairwise meta-analyses of teriparatide versus abaloparatide, then a Bayesian NMA comparing each to other treatments. Safety assessments included adverse events classified by MedDRA, with a particular attention to hypercalcemia and cardiac events. Seventeen studies (11 RCTs, 6 RWE) met inclusion criteria. Teriparatide and abaloparatide were effective in reducing vertebral and non-vertebral fractures in all pairwise meta-analyses versus placebo. Abaloparatide showed an advantage over teriparatide for non-vertebral fractures (OR: 0.87, 95% CI: 0.80-0.95) and hip fractures (OR: 0.81, 95% CI: 0.71-0.93). In the NMA model, teriparatide and abaloparatide were superior to placebo, raloxifene, and calcitonin in reducing vertebral fracture while teriparatide was further superior to denosumab and risedronate. For non-vertebral fracture, abaloparatide was better than any other treatment while teriparatide was only superior to alendronate or placebo. PTH1 analogs were better than placebo at reducing all fractures while no difference was observed for the risk of hip fracture. Both abaloparatide and teriparatide demonstrate comparable safety to other osteoporosis treatments, with no increased cardiovascular risk. This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of osteoporotic ankle fractures in South Korea: a nationwide retrospective cohort study (2006-2022).","authors":"Jung-Wee Park, Ha-Young Kim, Kyoung Min Kim, Jaiyong Kim, Hoyeon Jang, Jihye Kim, HoeJeong Chung","doi":"10.1007/s00198-025-07429-w","DOIUrl":"https://doi.org/10.1007/s00198-025-07429-w","url":null,"abstract":"<p><strong>Purpose: </strong>Ankle fractures, ranking as one of the very common osteoporotic fractures, pose a substantial socioeconomic burden. We aimed to investigate the incidence of elderly ankle fractures, refracture risks, and mortality rates in South Korea.</p><p><strong>Methods: </strong>Utilizing the Korean National Health Insurance Service (NHIS) registry from January 2006 to December 2022, individuals over 50 years with ankle fractures were identified. Osteoporotic ankle fractures were defined using admission diagnoses, procedural codes, and cast-related codes. Incidence rates, refracture rates, and one-year mortality rates were analyzed with standardization adjusted for gender and age distribution.</p><p><strong>Results: </strong>From 2006 to 2022, annual ankle fracture incidence rose from 193.90 to 278.83 per 100,000 person-years. Women exhibited 1.93 times higher incidence than men, with a notable increase in women. Most common in ages 60 to 69, ankle fracture rates increased until 2019 and after 2020 but decreased between 2019 and 2020. The one-year ankle refracture rates and osteoporotic refracture rates increased from 3.55% and 4.56% in 2007 to 9.32% and 10.37% in 2021, respectively. The one-year mortality rate after ankle fractures decreased from 2.10% in 2007 to 1.49% in 2021.</p><p><strong>Conclusion: </strong>This study offers insights into the epidemiology of osteoporotic ankle fractures in South Korea, revealing increasing incidence, gender differences, age-related patterns, and trends in refracture and mortality rates over the study period. This study examines the incidence, refracture risk, and mortality of osteoporotic ankle fractures in South Korea using a nationwide dataset (2006-2022). The incidence of ankle fractures increased significantly, especially in women, and refracture rates also rose, highlighting an unmet need for better osteoporosis management.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early administration of zoledronic acid after hip fracture.","authors":"Kevin McCarroll, James Mahon, Rosaleen Lannon, Aisling Carroll, Donal Fitzpatrick","doi":"10.1007/s00198-025-07450-z","DOIUrl":"https://doi.org/10.1007/s00198-025-07450-z","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.","authors":"Qing Zhang, Wenxue Gao, Xiaojuan Xu, Ran Cui, Bin Su","doi":"10.1007/s00198-025-07448-7","DOIUrl":"https://doi.org/10.1007/s00198-025-07448-7","url":null,"abstract":"<p><p>This study examined the link between baseline CTX levels and zoledronic acid's effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment.</p><p><strong>Purpose: </strong>To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis.</p><p><strong>Methods: </strong>This study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0.</p><p><strong>Results: </strong>A total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment.</p><p><strong>Conclusions: </strong>Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing trabecular bone score (TBS): clinical performance of TBS version 4.0 with direct correction for soft tissue thickness-the osteolaus study.","authors":"Guillaume Gatineau, Karen Hind, Enisa Shevroja, Elena Gonzalez-Rodriguez, Olivier Lamy, Didier Hans","doi":"10.1007/s00198-025-07421-4","DOIUrl":"https://doi.org/10.1007/s00198-025-07421-4","url":null,"abstract":"<p><p>This study compared TBS v4.0, which uses DXA-derived tissue thickness corrections, with TBS v3, which adjusts using BMI. TBS v4.0 improved soft tissue adjustments and maintained fracture risk prediction equivalence with TBS v3, enhancing applicability across diverse body compositions/phenotypes. Direct tissue thickness adjustment increases TBS's utility in osteoporosis assessment and management.</p><p><strong>Purpose: </strong>This study aimed to compare trabecular bone score (TBS) version 4.0, which uses direct tissue thickness correction via DXA measurements, with TBS version 3, which adjusts for soft tissues using body mass index (BMI). The objective was to assess the performance of TBS v4.0 compared to v3, for bone health evaluation and fracture risk assessment across diverse body compositions.</p><p><strong>Methods: </strong>Data from the OsteoLaus cohort were analyzed. Associations between TBS, BMI, DXA-measured tissue thickness, visceral fat (VFAT), and android fat were examined using regression and correlation analyses. Machine learning, including Random Forest (RF) and SHapley Additive exPlanations (SHAP), explored TBS changes between versions. Five-year fracture risk was assessed using FRAX adjustment, and logistic regression.</p><p><strong>Results: </strong>TBS v3 correlated with BMI (r = 0.110, p < 0 .001), VFAT mass (r =  - 0.162, p < 0 .001), and soft tissue thickness (r =  - 0.165, p < 0.001). TBS v4.0 demonstrated weaker correlations with BMI (r =  - 0.057, p > 0.999), VFAT Mass (r =  - 0.067, p > 0.779), and soft tissue thickness (r =  - 0.114, p = 0.019). Differences between TBS versions were investigated with SHapley Additive exPlanations (SHAP) and explained by BMI, tissue thickness, VFAT, and gynoid fat. Logistic regression and Delong's test revealed no significant differences in vertebral fracture prediction between the two TBS versions (p = 0.564). FRAX adjustments were highly consistent between versions (r = 0.994, p < 0.001), with no evidence of calibration bias (p = 0.241).</p><p><strong>Conclusion: </strong>TBS v4.0 enhances the adjustment for regional soft tissue effects and results suggest comparable vertebral fracture risk prediction to TBS v3. Explainable AI provided insights into the contributions of BMI, tissue thickness, visceral fat, and gynoid fat to the observed changes between TBS versions. Incorporating direct tissue thickness adjustment improves TBS applicability across diverse body sizes and compositions.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based joint statement position of perioperative bone optimization in the arthroplasty candidate, from FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM.","authors":"López-Cervantes Roberto Enrique, Torres-Naranjo Francisco, Etxebarria-Foronda Iñigo, Ojeda-Thies Cristina, Linares-Restrepo Francisco, Gonzalez-Reyes Miguel Angel, Caeiro-Rey Jose Ramón, Garin-Zertuche Dario Esau","doi":"10.1007/s00198-025-07411-6","DOIUrl":"10.1007/s00198-025-07411-6","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of patients living with joint replacements is increasing. Nearly two-thirds of patients undergoing elective arthroplasty procedures have low bone mineral density (LBMD), defined as osteopenia in 38.5% and osteoporosis in 24.8%; among those with osteoporosis, only 32.8% received treatment at the time of surgery.</p><p><strong>Materials and methods: </strong>A group of 7 national societies (FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM) developed a joint statement position on the diagnosis of osteoporosis and perioperative bone optimization in candidates for arthroplasty \"Arthroplasty Bone Optimization.\" We performed a scoping review of the available literature, followed by a systematic review and meta-analysis. Subsequently, a Delphi-modified method was used to gather the different positions.</p><p><strong>Results: </strong>After analyzing the literature, we came up with five recommendations: (1) Patients scheduled for elective arthroplasty should undergo a bone health assessment (BHA). (2) If poor bone quality is observed during surgery and a bone health assessment has not been conducted promptly, a complete BHA, including a DXA scan, is imperative. (3) In the arthroplasty candidate, if LBMD or osteoporosis are noticed, bone loss-related factors should be corrected, and appropriate treatment for osteoporosis should be started before or right after arthroplasty. The use of anti-resorptive and bone anabolic agents has been shown to reduce periprosthetic bone loss, complications, and non-septic revision rates after joint arthroplasty. (4) In arthroplasty candidates, the diagnosis of osteoporosis or low bone mineral density (LBMD) should not delay the surgery. (5) Monitoring central and periprosthetic bone mineral density through DXA protocols can help identify bone loss in central and periprosthetic areas in patients with risk factors or osteoporosis.</p><p><strong>Conclusions: </strong>Perioperative bone optimization should be considered in all patients who are candidates for arthroplasty. The orthopedic surgeon and multidisciplinary team should be encouraged to diagnose and treat the arthroplasty candidates' bone by screening for bone loss-related factors and diagnosing osteoporosis and starting treatment according to the current international guidelines. Following these recommendations could reduce periprosthetic bone loss, complications, and aseptic revision rates following arthroplasty surgery. More research is needed to understand the implications of osteoporosis and its treatment for joint replacement outcomes and long-term survival.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"375-389"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-processed food intake and prevalence of osteoporosis in US adults aged 50 years and older: a cross-sectional analysis.","authors":"Emma L Greatorex Brooks, Christy C Tangney, Ethan M Ritz","doi":"10.1007/s00198-025-07394-4","DOIUrl":"10.1007/s00198-025-07394-4","url":null,"abstract":"<p><p>Dietary quality may be a factor in the progression of non-communicable, chronic diseases. This analysis of NHANES data demonstrates association between consumption of UPF and prevalence of osteoporosis and osteopenia in adults 50 years and older. UPF intake is an important consideration when recommending dietary patterns for optimum bone health PURPOSE: Declining bone mineral density in older adults can result in osteoporosis, leading to decreased physical function, quality of life, and increased risk of mortality. Poor dietary quality may contribute to the progression of this disease. This study explores the association between the consumption of ultra-processed foods (UPF) and the prevalence of osteoporosis and osteopenia in adults aged 50 years and older.</p><p><strong>Method: </strong>Using regression analysis and adjusting for covariates, 24-h recall data from adults 50 years and over in four cycles of NHANES were examined for associations between prevalence of osteoporosis and intakes of UPF as a proportion of daily energy intake.</p><p><strong>Results: </strong>Mean (SE) intake of UPF as a proportion of total daily energy ranged from 29.5% (0.3) in the lowest quintile to 76.3% (0.3) in the highest. 50.5% of women and 28.0% of men had osteopenia, 8.2% and 1.8%, respectively, had osteoporosis. Increased risk of osteopenia or osteoporosis was observed in the highest quintile of UPF intake compared to that of the lowest: OR 1.52 (95% CI 1.28, 1.79). The odds of self-reported prior fractures at hip, wrist, or spine in women increased by 1.9% for every percentage increase in proportion of UPF intake (95% CI 1.003, 1.035). Increased risk of fracture was not observed among men.</p><p><strong>Conclusions: </strong>These findings indicate an association between osteoporosis and osteopenia and the intake of UPF as a proportion of total daily energy. Further investigation into the impact of dietary quality on osteoporosis and fracture risk is warranted, particularly in post-menopausal women.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"455-464"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}